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Objective: Low testosterone level may be a reversible
risk factor for functional disability and deterioration in
patients with chronic obstructive pulmonary disease
(COPD). We sought to systematically assess the
endogenous testosterone levels and effect of testosterone
therapy on exercise capacity and health-related quality of
life (HRQoL) outcomes in COPD patients, as well as to
inform guidelines and practice.
Design: Systematic review and meta-analysis.
Data sources:We searched PubMed, Scopus, Cochrane
Library, CINAHL, Health Source Nursing and PsychINFO
and the reference lists of retrieved articles published before
May 2012.
Inclusion criteria: Observational studies on endogenous
testosterone levels in people with chronic lung disease
compared with controls, or randomised controlled trials
(RCTs) on testosterone therapy for exercise capacity and/
or HRQoL outcomes in COPD patients were eligible.
Data extraction and analysis: Data on the mean
difference in endogenous total testosterone (TT) values,
and the mean difference in exercise capacity and HRQoL
values were extracted and pooled using random effects
meta-analysis.
Results: Nine observational studies in 2918 men with
COPD reported consistently lower levels of TT compared
with controls (weighted mean difference was –3.21 nmol/
L (95% CI −5.18 to −1.23)). Six RCTs in 287 participants
yielded five studies on peak muscle strength and peak
cardiorespiratory fitness outcomes (peak oxygen uptake
(VO2) and workload) and three studies on HRQoL
outcomes. Testosterone therapies significantly improved
peak muscle strength (standardised mean difference
(SMD) was 0.31 (95% CI 0.05 to 0.56)) and peak
workload (SMD was 0.27 (95% CI 0.01 to 0.52))
compared with control conditions (all but one used
placebo), but not peak VO2 (SMD was 0.21 (95% CI
−0.15 to 0.56)) or HRQoL (SMD was –0.03 (95% CI
−0.32 to 0.25)).
Conclusions:Men with COPD have clinically relevant
lower than normal TT levels. Insufficient evidence from
short-term studies in predominately male COPD patients
suggests that testosterone therapy improves exercise
capacity outcomes, namely peak muscle strength and
peak workload.
INTRODUCTION
Chronic obstructive pulmonary disease
(COPD) is currently ranked the ﬁfth leading
cause of global disability (health loss).1
Health status or health-related quality of life
(HRQoL) is a clinically important measure-
ment of disability among patients with COPD
for prognostic studies and trials.2–4 Exercise
capacity, one of the main determinants of
HRQoL, is signiﬁcantly impaired in COPD
patients.3 5 Dyspnoea and fatigue due to skel-
etal muscle dysfunction, among other
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physiological abnormalities, are cardinal symptoms that
limit exercise capacity in COPD patients.6 This is partly
due to decreases in muscle strength and mass (often
called ‘cachexia’), since they are characteristic features
of skeletal muscle dysfunction contributing to exercise
intolerance and consequential deterioration in
HRQoL.5 6 Conversely, pulmonary rehabilitation (PR)
including exercise (namely resistance training (RT))
leads to clinically relevant improvements in muscle
strength and HRQoL,7 8 indicating that skeletal muscle
dysfunction should be a primary therapeutic target for
intervention in patients with COPD.
Since the testosterone level has been shown to be posi-
tively associated with muscle strength and cardiorespira-
tory ﬁtness accounting for physical activity and muscle
mass,9 10 a low testosterone level may be an independent
risk factor for functional disability and deterioration in
COPD. For example, the levels of testosterone and other
androgenic hormones were decreased in male and
female COPD patients compared with controls in a few
studies.11–13 The potential mechanisms for this endo-
crine dysfunction most likely involve hypoxaemia, hyper-
capnia, systemic inﬂammation and the use of
glucocorticoids.14
Thus, it is important to reliably establish whether the
mean endogenous testosterone level is decreased in
patients with COPD, because this condition is reversible
with testosterone supplementation therapy. Indeed, a
small but promising body of randomised controlled trial
(RCT) evidence suggests that testosterone therapy
improves exercise capacity and HRQoL without increas-
ing serious adverse events.15–17 While it is difﬁcult to
explain this apparent therapeutic beneﬁt, increased
cardiac output,18 haemoglobin and haematocrit,19 baror-
eﬂex sensitivity20 and exercise tolerance due to improve-
ments in peak oxygen uptake (peak VO2) and muscle
strength20 are all plausible mechanisms.
However, our initial analysis of the available published lit-
erature indicates an absence of a systematic review of relevant
studies on endogenous testosterone levels and testosterone
therapy in patients with COPD. We therefore sought to sys-
tematically review previous research to assess the mean
endogenous testosterone level in people with chronic lung
disease compared with controls, and the effects of testoster-
one therapies on exercise capacity and HRQoL outcomes in
COPD patients, to inform guidelines and practice.
METHODS
Search strategy
We searched PubMed, Scopus, Cochrane Library,
CINAHL, Health Source Nursing and the PsychINFO
electronic databases for articles published before May
2012. Search syntaxes were developed in consultation
with an experienced university research librarian taking
into account a broad range of terms and phrases used in
deﬁnitions of testosterone and COPD (full electronic
search strategies for the PubMed, Scopus and Cochrane
Library databases in online supplementary appendix
pages 1 and 2). Reference lists of potentially eligible arti-
cles were searched by hand to identify additional studies
missed by our search strategy.
Study selection
One reviewer (EA) identiﬁed potentially relevant studies
for inclusion by screening titles and/or abstracts of all
citations identiﬁed with our database searches. A second
screening was performed on the full text of these arti-
cles. Observational studies in adult populations that
reported endogenous testosterone levels in men and/or
women (separately) with chronic lung disease (cases)
compared with controls, or RCTs that reported the
effects of testosterone treatment on exercise capacity
and HRQoL outcomes in COPD patients were eligible.
There were no language restrictions for articles.
Data extraction
Data extraction and quality assessment of included
studies were performed and/or veriﬁed independently
by three reviewers (EA, BC and SS). Discrepancies were
resolved through discussion. Authors of relevant studies
were contacted, where possible, for data that could not
be extracted from the published articles.
Quality assessment
For methodology and quality assessment, quality check-
lists were developed to identify potential sources of bias
(tables in online supplementary appendix pages 3 and
4). Quality items for observational studies reviewed were
(each worth 1 numerical point) as follows: (1) COPD or
chronic lung disease was reported to have been clinically
diagnosed or categorised according to the WHO
International Statistical Classiﬁcation of Diseases and
Related Health Problems (ICD) system, (2) endogenous
testosterone level was measured by radioimmunoassay or
liquid chromatography-tandem mass spectrometry,
(3) the study population was representative of the clin-
ical setting or community (ie, demographic characteris-
tics of cases and hospital controls were typical and
community cases or controls were randomly selected)
and (4) there was adequate adjustment or exclusion or
matching for covariates known to be associated with
COPD and hypogonadism in men (each worth 0.2
numerical point): (a) age, (b) socioeconomic or partner
status, (c) central or general obesity, (d) smoking status,
(e) alcohol intake, (f) physical activity, (g) depression
or anxiety (or medications), (h) metabolic syndrome or
cardiovascular disease (or medications), (i) systemic
inﬂammation (or glucocorticoids) and ( j) sleep apnoea
(or treatments).
Quality items for RCT studies reviewed were (each
worth 1.0 numerical point) as follows: (1) study eligibil-
ity criteria were adequately described, (2) randomisation
methodology was adequate (ie, evidence suggesting that
the ‘random’ method was used to generate and imple-
ment random allocation sequence), (3) allocation
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concealment was adequate (ie, evidence to suggest that
a robust method was used for concealing the sequence
of treatment allocation (eg, independent IT or tele-
phone service or sealed opaque envelopes only opened
in front of the participant), (4) between-group prognos-
tic indicators were balanced (ie, evidence showing that
groups were similar at the outset for these prognostic
indicators), (5) care providers were blinded to treatment
allocation, (6) between-group drop-out rates were
balanced, (7) intention-to-treat analysis was included
and (8) adverse events were reported.
Our quality checklist scales were designed based on
criteria for assessment of observational studies21 and
RCTs21 22 and allowed summed scores to range from 0
to 5 points and from 0 to 8 points, respectively, reﬂect-
ing lowest to highest quality. Studies were considered
‘better quality’ if they received a score of 3 or higher for
observational studies and of 5 or higher for RCTs, since
that meant that they had most of our quality items.
Primary outcomes
The primary outcomes were the mean difference in
endogenous total testosterone (TT) values between the
case and control groups for observational studies (the
most frequently reported testosterone outcome in relevant
studies), and the mean difference in exercise capacity and
HRQoL values after intervention (post-treatment)
between the treatment and control groups for RCTs.
Where necessary for observational studies, we estimated
the mean and variance from the median, range and
sample size using methods which have been shown to be
reasonably robust in non-extreme circumstances.23 Where
necessary for RCTs, the post-treatment means were
derived from the within-group changes and the control
group SD carried forward from the baseline values.24
Standardised mean differences (SMDs) were calculated
using Glass’ Delta method. Exercise capacity outcomes
included any assessment of cardiorespiratory ﬁtness and
peripheral skeletal muscle strength. Where multiple car-
diorespiratory ﬁtness outcomes were reported, we ﬁrst
chose peak VO2 measures and then prioritised peak work-
load (power output) laboratory assessments of cardio-
respiratory ﬁtness over ﬁeld tests. Where multiple muscle
strength outcomes were reported, we prioritised peak iso-
metric measures over peak dynamic measures and knee
extension over other joint movements. HRQoL outcomes
included any patient-reported assessment of health status
or functional disability. Where multiple HRQoL out-
comes/scales were reported, we ﬁrst chose summed score
scales, and then prioritised subscales that measure
‘fatigue’ symptoms, and the most frequently reported
HRQoL outcome in the other studies reviewed.
Data synthesis
Three reviewers (EA, BC and SS) independently collated
and/or veriﬁed extracted data to present a descriptive
synthesis of important study characteristics and a quanti-
tative synthesis of effect estimates.
Secondary outcomes
The secondary outcomes were data about adverse events
reported in RCTs for a descriptive synthesis.
Statistical methods
We pooled and weighted studies ﬁrst using random
effects meta-analysis models, and second using ﬁxed
effects models for veriﬁcation.25 Where necessary, we
standardised laboratory values for endogenous TT levels
between observational studies using the International
System of Units (SI units), expressed in nanomoles per
litre (nmol/L). These studies were then pooled to esti-
mate the inverse variance weighted mean difference
(WMD), including the DerSimonian and Laird 95% CI,
between cases and controls. Where papers presented
medians without means, we estimated the missing mean
as being equal to the median for meta-analysis.23
In examining the effects of testosterone treatment on
exercise capacity and HRQoL outcomes, the SMD from
each RCT was pooled to produce an overall estimate of
effect, and associated 95% CI, between the treatment
and control groups. For each meta-analysis model, the
degree of heterogeneity in SMDs was assessed by visual
inspection, the I2 statistic (moderate being <50%26) and
the χ2 test of goodness of ﬁt.27 Where evidence of het-
erogeneity was observed, we checked data extracted
from individual outlier studies, qualitatively investigated
reasons for their different results and explored the
effects of study exclusion in sensitivity analyses.
We also used sensitivity analysis to investigate the
robustness of the meta-analyses models. We variously
excluded RCTs in men and women, placebo only
(rather than placebo with exercise) controlled trials,
longer duration trials (≥12 weeks) and studies of lower
quality (score <3 for observational studies; score <5 for
RCTs). And we repeated the meta-analysis models using
different cardiorespiratory ﬁtness outcomes. Publication
bias, which reﬂects the tendency for smaller studies to
be published in the literature only when the ﬁndings are
positive, was assessed visually using funnel plots.28 All cal-
culations were performed in Stata V.12 (StataCorp,
College Station, Texas, USA) using the ‘metan’ and
‘metafunnel’ commands. A two-tailed p value <0.05 was
considered statistically signiﬁcant throughout the
analyses.
RESULTS
Figure 1 presents a ﬂow chart summarising the identiﬁ-
cation of potentially relevant studies, as well as those
included and excluded (see online supplementary
appendix page 8). Our search strategy identiﬁed 906
citations after the duplicates were removed. Of these,
865 citations were excluded after the ﬁrst screening of
titles and/or abstracts for inclusion and exclusion cri-
teria, leaving 41 citations for a second full text screen-
ing. Hand searching the reference lists of these articles
identiﬁed two additional potentially relevant citations.
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After further assessment of these 43 citations, 28 were
excluded for reasons listed in ﬁgure 1, leaving 15 for
ﬁnal inclusion in the systematic review. Most studies were
excluded for inadequate predictor or outcome variables,
or for not having a control group (list of excluded cita-
tions; see online supplementary appendix pages 5–7).
Descriptive data synthesis
Table 1 presents the study characteristics of nine obser-
vational studies included for review, which were pub-
lished between 1981 and 2011. Studies were conducted
in Scotland,29 30 Sweden,31 the USA,32 Taiwan,33
Greece,12 Turkey,13 Norway34 and Belgium.35 The
degree of severity of airﬂow limitation in COPD cases
ranged from mild-to-very severe, assessed according to
the Global Initiative for Chronic Obstructive Lung
Disease criteria36 in four studies,12 13 33 35 and by various
spirometry criteria in four29 30 32 34 of the ﬁve remaining
studies. Control participants were recruited from
primary care settings in six studies.12 29 30 32 33 35 The
sample sizes ranged from 16 to 213, resulting in a total
of 2918 participants across studies. The mean age of the
samples ranged from 50 to 71 years. All the observa-
tional studies were conducted in men. The mean quality
scores ranged from 2.2 to 4, and four studies received a
score of 3 or higher.12 13 32 34
Table 2 presents the study characteristics of six RCTs
included for review, which were published between 2003
and 2011. Studies were conducted in the USA,37 The
Netherlands,38 Brazil,39 France,16 Canada40 and Norway.41
Major inclusion criteria were stable COPD or chronic
respiratory failure in all studies, various spirometry criteria
in all but one study,16 low TT in only one study37 and low
body mass index in only two studies.16 39 Major exclusion
criteria were a range of chronic conditions in all studies,
prostatic conditions in four studies16 37 39 40 and elevated
haemoglobin in one study.37 The sample sizes ranged
from 16 to 122, resulting in a total of 287 participants
across studies. The mean age of the samples ranged from
66 to 69 years. All but two studies16 40 were conducted in
men only. The baseline mean TT levels ranged from 9.6 to
21.6 nmol/L for men, and from 0.42 to 0.45 nmol/L for
women as reported in one study.16 The testosterone therap-
ies used were oral testosterone undecanoate in one study,16
oral stanozolol after a baseline intramuscular injection of
testosterone in another study39 and intramuscular injec-
tions (testosterone enanthate37 41 and nandrolone decano-
ate38) in all the remaining studies. Four studies investigated
Figure 1 Flow chart summarising identification of studies included for review.
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Table 1 Characteristics of observational studies reviewed
Participants



























32 M 69 14.3 6.9 17.9 6.9 Age 1.2










Age, thyroid disease, oral
corticosteroids
2.9



























































































































16 M 50 13.1 4.4 20.3 5.4 Age 2.7











2197 M 66 12.7 5.3 14.0 5.5 Age, waist circumference,
smoking status
3.6













BMI, body mass index; BTS, British Thoracic Society; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in1 s; FVC, forced vital capacity; GOLD, Global Initiative for






































size Major inclusion criteria Major exclusion criteria Sex (M/W) Mean age (years) Treated Controls
Casaburi et al37 USA 47 Stable COPD, spirometry FEV1
≤60% predicted and FEV1/VC
≤60%; total testosterone
≤13.9 nmol/L









Creutzberg et al38 The Netherlands 56 Stable COPD, ATS criteria,
spirometry FEV1 <70% predicted




disorders, type 1 diabetes,
oxygen dependency at rest
M 66 13.4 14.6
Ferreira et al39 Brazil 17 Ambulatory and stable COPD,
spirometry maximal inspiratory
pressure <60% predicted and
BMI <20 kg/m2
CVD, prostatic indications M 69 14.4 17.2
Pison et al16 France 122 Stable CRF, >18 years, PaO2
≤8 kPa, long-term oxygen
therapy and/or home mechanical
ventilation >3 months, BMI









women of childbearing age,
elevated aminotransferase




Sharma et al40 Canada 16 Stable COPD, GOLD criteria
stage 3–4, spirometry FEV1
<50% predicted and FEV1/FVC
<0.7






M/W 68 M NR W NR
Svartberg et al41 Norway 29 Stable COPD, moderate to
severe, spirometry FEV1 <60%
predicted
Asthma, malignancies, CVD,
hepatic or endocrine disease







































(a) Testosterone enanthate, 100 mg/
week IM; (b) Testosterone enanthate,
100 mg/week IM with RT
(a) Placebo; (b) Placebo with RT 10 Muscle strength (leg press, 1RM kg); cardiorespiratory fitness
(bicycle, peak VO2 L/min and peak workload Watts)
5.0
Nandrolone decanoate, 50 mg/
2 weeks IM
Placebo 8 Muscle strength (knee extension, peak isometric force
Newtons); cardiorespiratory fitness (bicycle, peak workload
Watts and peak VO2 mL/min); HRQoL (SGRQ total score)
6.0
Testosterone, 250 mg IM at baseline
and oral stanozolol, 12 mg/day with
PR
Placebo with PR 9–27 weeks 27 Cardiorespiratory fitness (bicycle, peak VO2% predicted;
6MWT, distance metres)
5.0
Oral testosterone undecanoate, M
80 mg/W 40 mg twice daily with PR
Home education on
self-management of
COPD-related stress and anxiety
13 Muscle strength (knee extension, peak isometric force
Newtons); cardiorespiratory fitness (6MWT, distance metres;
bicycle, peak workload Watts); HRQoL (CRQ total score)
5.0
Nandrolone decanoate, M 50 mg/W
25 mg/2 weeks IM with PR
Placebo with PR 16 Muscle strength (knee extension, peak isometric force units
NR); cardiorespiratory fitness (bicycle, peak VO2% predicted
and peak workload Watts; 6MWT, distance metres); HRQoL
(CRQ fatigue subscore)
4.5
Testosterone enanthate, 250 mg/
4 weeks IM
Placebo 26 Cardiorespiratory fitness (6MWT, distance metres) 5.5
1RM, one repetition maximum; 6MWT, 6 min walking test; ATS, American Thoracic Society; BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRF, chronic respiratory
failure; CRQ, chronic respiratory questionnaire; CVD, cardiovascular diseases; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive































the combined effects of testosterone therapy with RT37 or
PR.16 39 40 All but one study16 used placebo control condi-
tions. Trial durations ranged from 8 to 27 weeks. Primary
outcomes were peak muscle strength in ﬁve studies (from
four citations16 37 38 40), peak VO2 in ﬁve studies (from
four citations37–40), peak workload in ﬁve studies
(from four citations16 37 38 40), 6 min walking test (6MWT)
in four studies16 39–41 and HRQoL in three studies.16 38 40
The mean quality scores ranged from 4.5 to 6, and all but
one study40 received a score of 5 or higher.
Quantitative data synthesis
Effect of COPD exposure on an endogenous TT level
Figure 2 presents WMD on an endogenous TT level
between the case and control groups for observational
studies (see online supplementary appendix page 9).
Men with COPD had signiﬁcantly lower levels of TT com-
pared with controls (pooled WMD was –3.21 nmol/L
(−5.18 to −1.23)). There was a high degree of heterogen-
eity between studies (I2=81.9%, p<0.001) that was mostly
a result of variation in the degree of deference rather
than an unfavourable direction towards the null. The sen-
sitivity analyses presented in table 3 show that the pooled
WMD was substantially changed after exclusion of lower
quality studies (increased to –3.68 (−7.00 to −0.36)) and
one large sample size study34 (increased to –3.56 (−5.63
to −1.49)). Finally, for the one study33 which provided
unadjusted mean differences and mean differences
adjusted for age, waist circumference and smoking status,
a model using unadjusted rather than adjusted values
decreased the pooled WMD to −2.95 (−4.63 to −1.27).
In addition, a funnel plot was produced which showed
only slight evidence of publication bias, since WMD in
TT was small (−0.6033 and −1.10 nmol/L34) for two of
the largest studies (ﬁgure 3; see online supplementary
appendix page 10).
Figure 2 Weighted mean difference in the endogenous total testosterone level between the case and control groups for
observational studies.









Fixed effects model 9 2918 −3.00 (−3.75 to −2.26) <0.001
Exclusion of five lower quality studies
(score <3)
4 2532 −3.68 (−7.00 to −0.36) <0.001
Model using unadjusted rather than
adjusted values in one study
9 2918 −2.95 (−4.63 to −1.27) <0.001
Exclusion of a large sample size study 8 721 −3.56 (−5.63 to −1.49) <0.001
COPD, chronic obstructive pulmonary disease; N, number; WMD, weighted mean difference.
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Effect of testosterone therapy on exercise capacity and
HRQoL outcomes
Figure 4 presents SMD in peak muscle strength out-
comes after testosterone therapy between the treatment
and control groups for RCTs (see online supplementary
appendix page 11). Testosterone therapies signiﬁcantly
improved standardised peak muscle strength outcomes
compared with control conditions (pooled SMD was
0.31 (0.05 to 0.56)), and there was little evidence of stat-
istical heterogeneity between studies (I2=0%, p=0.839).
The sensitivity analyses presented in table 4 shows that
the pooled SMD was similar after exclusion of one lower
quality study40 (0.31 (0.04 to 0.57)), but was substantially
changed after exclusion of two placebo only controlled
studies (no longer statistically signiﬁcant 0.30 (−0.01 to
0.62)), and the two studies in men and women that were
also the two longer duration studies16 40 (decreased to
0.21 (−0.18 to 0.60)). In addition, a funnel plot was pro-
duced which showed only slight evidence of publication
bias, since SMD in peak muscle strength outcomes was
consistent in all but one treatment arm in one study37
(ﬁgure 5; see online supplementary appendix page 12).
Figure 6 presents SMD in peak VO2 outcomes after
testosterone therapy between the treatment and control
groups for RCTs (see online supplementary appendix
page 13). Testosterone therapies consistently failed to
show signiﬁcant improvements in standardised peak
VO2 outcomes compared with control conditions
(pooled SMD was 0.21 (−0.15 to 0.56); I2=4.8%,
p=0.379). The sensitivity analyses presented in table 5
shows that this null effect was similar after exclusion of
one lower quality study40 (0.13 (−0.27 to 0.54)), two
placebo only controlled studies (0.03 (−0.60 to 0.66)),
one study in men and women40 (0.13 (−0.27 to 0.54)),
and two longer duration studies39 40 (0.27 (−0.12 to
0.67)), and in the model using 6MWT outcomes (0.10
(−0.34 to 0.53)). Conversely, testosterone therapies sig-
niﬁcantly improved cardiorespiratory ﬁtness in the
model using peak workload rather than peak VO2 out-
comes (pooled SMD was 0.27 (0.01 to 0.52)), and there
was little evidence of statistical heterogeneity between
studies (I2=0%, p=0.741).
Figure 7 presents SMD in peak HRQoL outcomes
after testosterone therapy between the treatment and
control groups for RCTs (see online supplementary
Figure 3 Funnel plot assessing symmetry of the weighted
mean difference in the total testosterone level between the
case and control groups for observational studies.
Figure 4 Standardised mean difference in peak muscle strength outcomes after testosterone therapy between the treatment
and control groups for randomised controlled trials.
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appendix page 14). Testosterone therapies consistently
failed to show better standardised HRQoL outcomes
compared with control conditions (pooled SMD was –
0.03 (−0.32 to 0.25); I2=0%, p=0.934). The sensitivity
analyses showed that this null effect was comparable in
the ﬁxed effects model (−0.03 (−0.32 to 0.25)) and
after exclusion of one lower quality study40 (−0.04
(−0.34 to 0.25)).
Adverse events
Two RCTs showed that testosterone therapy was asso-
ciated with more serious adverse events compared with
the control group. One study reported an increased
number of exacerbations during short-term, but not long-
term, follow-up,16 and another study reported that two of
three COPD patients with respiratory failure in the treat-
ment group had died.38 Conversely, one study reported
that more patients died of respiratory failure in the
control group.39 Four studies showed that testosterone
therapies decreased gonadotrophin levels compared with
controls, as can be expected.16 37 39 41 Compared with
controls, testosterone therapy was associated with a
decrease in the sex hormone-binding globulin level in
two studies,16 41 and a decrease in the oestradiol level in
men in another study.16 Finally, few studies showed that
testosterone therapy was associated with relative increases
in haemoglobin or haematocrit;16 37 38 creatinine, aspar-




We have established that men with COPD have signiﬁ-
cantly lower levels of endogenous TT compared with
controls (WMD was −3.21 nmol/L (−5.18 to −1.23)).
The size of the mean difference in TT level, which ranks
men with COPD in the second quartile (below average)
compared with age-matched population norms,9 is likely
to be clinically relevant. For instance, comparable or
greater differences in TT levels between cases and con-
trols have been reported in studies on risk of type 2 dia-
betes (WMD was −2.66 nmol/L (−3.45 to −1.86)),42
metabolic syndrome (WMD was −2.64 nmol/L (−2.95 to
−2.32))43 and clinically signiﬁcant depression (median
difference was –1.21 nmol/L, p<0.001 for Mann-Whitney
test).44 These comorbidities have been shown to
adversely affect COPD prognosis,45–47 and would further
complicate COPD management. As the effect of COPD
exposure on TT level increased in size after exclusion of
lower quality studies and one large sample size study,
future higher quality studies will most likely strengthen
rather than weaken this evidence base. Collectively, our
results and the existing literature indicate that testoster-
one deﬁciency should be considered in men with
COPD.
On the basis of the limited short-term RCT evidence in
predominately male COPD patients, our results suggest
that testosterone therapy signiﬁcantly improves several
exercise capacity outcomes. The size of the effect of testos-
terone therapy that can be expected in practice is small to
moderate, but comparable to exercise or PR therapies
alone.7 8 The effect of testosterone therapy on standar-
dised muscle strength outcomes remained robust after
exclusion of one lower quality study, but weakened after
exclusion of two placebo only studies. This supports the
hypothesis that testosterone therapy with exercise is more
effective than testosterone therapy alone for functional
improvements.48 In addition, our results suggest that the
Table 4 Sensitivity analysis of randomised controlled trials on testosterone treatment → muscle strength outcomes
meta-analysis
N studies N sample SMD (95% CI)
p Value for
heterogeneity
Fixed effects model 5 241 0.31 (0.05 to 0.56) 0.839
Exclusion of one lower quality study (score <5.0) 4 225 0.31 (0.04 to 0.57) 0.699
Exclusion of two placebo only control studies 3 161 0.30 (−0.01 to 0.62) 0.491
Exclusion of two studies in men and women 3 103 0.21 (−0.18 to 0.60) 0.611
Exclusion of two longer duration studies (≥12 weeks) 3 103 0.21 (−0.18 to 0.60) 0.611
N, number; SMD, standardised mean difference.
Figure 5 Funnel plot assessing symmetry of standardised
mean difference in peak muscle strength outcomes after
testosterone treatment between the treatment and control
groups for randomised controlled trials.
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mechanism for improvement in cardiorespiratory ﬁtness
assessed by peak workload is most likely explained by
better exercise tolerance due to testosterone-induced
increases in muscle strength rather than changes in VO2.
Limitations
Several limitations require careful consideration. Since
only a small number of studies conducted in speciﬁc
populations were included, the ﬁndings of this review
may not be relevant to other countries and key groups,
which will require further research. In particular, most
of the RCTs were conducted in COPD patients without
cardiovascular disease and/or diabetes or endocrine
disease, which are highly prevalent in this population
group.46 Second, we replaced missing data points with
estimates in some instances, which introduced further
uncertainty. This includes estimating the mean from the
median and range and carrying forward the preinterven-
tion SD of control groups where the postintervention
statistic was not available. Third, because only a few
RTCs targeted COPD patients who would have theoretic-
ally beneﬁted most from testosterone therapy such as
those with low testosterone or body weight,16 37 39 our
estimated effect size for improvement in standardised
exercise capacity may have been underestimated. Finally,
the reviewer-level limitations include incomplete
retrieval of information for several of the 28 citations
excluded, as well as the existence of other relevant
studies not identiﬁed with our search strategy, resulting
in selection bias. However, the results and conclusions
reported in most of the excluded studies were in line
with those reported here, and selection bias was unlikely.
Figure 6 Standardised mean difference in peak VO2 outcomes after testosterone therapy between the treatment and control
groups for randomised controlled trials.





sample SMD (95% CI)
p Value for
heterogeneity
Fixed effects model 5 136 0.21 (−0.13 to 0.56) 0.379
Exclusion of one lower quality study (score <5) 4 120 0.13 (−0.27 to 0.54) 0.315
Exclusion of two placebo only control studies 3 56 0.03 (−0.60 to 0.66) 0.269
Exclusion of one study in men and women 4 120 0.13 (−0.27 to 0.54) 0.315
Exclusion of two longer duration study
(≥12 weeks)
3 103 0.27 (−0.12 to 0.67) 0.553
Model using peak workload rather than peak VO2
outcomes
5 241 0.27 (0.01 to 0.52) 0.741
Model using 6MWT rather than peak VO2
outcomes
4 184 0.10 (−0.34 to 0.53) 0.210
6MWT, 6 min walking test; N, number; SMD, standardised mean difference.
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Nevertheless, our systematic analysis of the existing lit-
erature revealed that there is an absence of sufﬁcient
RCT evidence to draw ﬁrm conclusions about the long-
term beneﬁts and risks of testosterone therapies for
exercise capacity and HRQoL outcomes in male or
female COPD patients, or about the pharmacological
dosing for speciﬁc testosterone therapies needed for
effectiveness. Reliable information on the efﬁcacy and
safety, as well as cost-effectiveness, of speciﬁc testosterone
therapies is required to inform clinical practice guide-
lines for COPD. In addition, future high-quality epi-
demiological research is needed to determine which
subgroups of COPD patients are most vulnerable to tes-
tosterone deﬁciency, and to reliably establish whether
women with COPD likewise present with signiﬁcantly
lower levels of TT than controls.
CONCLUSIONS
Men with COPD have clinically relevant lower than
normal endogenous TT levels, and we believe that our
meta-analytic results are sufﬁciently reliable to recom-
mend that clinicians should consider testosterone deﬁ-
ciency in these patients. Although our results also
suggest that testosterone therapy improves several exer-
cise capacity outcomes, there is an absence of sufﬁcient
RCT evidence to draw ﬁrm conclusions about the long-
term beneﬁts and risks of testosterone therapy for exer-
cise capacity and HRQoL outcomes in male or female
COPD patients.
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